A new hormonal therapy for estrogen receptor-negative breast cancer

World Journal of Surgery

Volumn 31, Issue 5, 2007, Pages 1041-1046

  Hardin, Chelsea ^a   Pommier, Rodney ^a   Calhoun, Kristine ^a   Muller, Patrick ^a   Jackson, Terisa ^a   Pommier, SuEllen ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANDROGEN RECEPTOR; ESTROGEN RECEPTOR; METHYLTHIOTETRAZOLE; PRASTERONE SULFATE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; EXPERIMENTAL STUDY; FLUORESCENCE; GENE EXPRESSION; HORMONAL THERAPY; HUMAN; HUMAN CELL; NICK END LABELING; REAL TIME POLYMERASE CHAIN REACTION;

BREAST NEOPLASMS; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU NICK-END LABELING; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 34248175006     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-007-0694-8     Document Type: Article

References (11)

1. McGuire WL. An update on estrogen and progesterone receptors in prognosis for primary and advanced breast cancer. In Iacobelli S, editors, et al. Hormones and Cancer vol. 15, Raven Press, New York, 1980;pp 337-344.
2. Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol 1993;170:31-35.
3. Brys M, Wojcik M, Romanowicz-Makowska H, Krajewska WM. Androgen receptor status in female breast cancer: RT-PCR and Western blot studies. J Cancer Res Clin Oncol 2002;128:85-90.
4. Henderson IC, Canellos GP. Cancer of the breast: The past decade. N Engl J Med 1980;302:17-30, 78-80.
5. Goldenberg IS, Waters N, Ravdin RS, et al. Androgenic therapy for advanced breast cancer in women. A report of the Cooperative breast Cancer Group. JAMA 1973;223:1267-1268.
6. Manni A, Arafah BM, Pearson OH. Androgen-induced remissions after antiestrogen and hypophysectomy in stage IV breast cancer. Cancer 1981;48:2507-2509.
7. Litvinov IV, Antony L, Isaacs JT. Molecular characterization of an improved vector for evaluation of the tumor suppressor versus oncogene abilities of the androgen receptor. Prostate 2004;61:299-304.
8. Toth-Fejel S, Cheek J, Calhoun K, et al. Estrogen and androgen receptors as comediators of breast cancer cell proliferation. Arch Surg 2004;139:50-54.
9. Morris KT, Toth-Fejel S, Schmidt, Fletcher WS, Pommier RF. High DHEA-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: A renewed role for adrenalectomy. Surgery 2001;130:947-953.
10. Harrell JC, Dye WW, Allred DC, et al. Estrogen receptor positive breast cancer metastases: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res 2006;66:9308-9315.
11. Trivieri L Jr, Anderson JW. Natural hormone replacement therapy. In Trivieri L Jr, editor, Alternative Medicine, the Definitive Guide. Celestial Arts, Berkeley, 2002;370-371.